Food & Wine
RXi Pharmaceuticals to Webcast Presentation at BioCentury Future Leaders in the Biotech Industry Conference
WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the Companya™s President and Chief Executive Officer, Mark J. Ahn, Ph.D., will present a corporate overview to include the companya™s recent announcement of their intent to acquire Apthera at BioCenturya™s Future Leaders Conference on Friday, April 15, 2011 at 9:00 a.m. ET, at the Millennium Broadway Hotel & Conference Center in New York City.
The acquisition provides RXi with a late stage product candidate, NeuVaxa", a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, not eligible for Herceptin®, which is expected to enter Phase III clinical trials in the first half of 2012. The Companya™s first RNAi product, RXI-109 which targets CTGF (connective tissue growth factor) for anti-scarring, remains on track for an investigational new drug (IND) application filing this year.
A live webcast of the presentation will be available from the aInvestor Relationsa section of the Company's website, [ www.rxipharma.com ]. A replay of the presentation will be available for 30 days.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies. Based on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXia™s first RNAi product candidate, RXI-109 which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials in anti-scarring in early 2012. RXi recently accelerated its product development focus with the acquisition of NeuVaxa" which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®, in the first half of 2012. For more information please visit us at [ www.rxipharma.com ]